Dan Kaufman, MD, PhD
Professor of Medicine
Mayo Medical School
University of Wisconsin Hospital and Clinics, (Internal Medicine)
University of Wisconsin Hospital and Clinics (Hematology/BMT)
Mayo Graduate School
Dr. Kaufman is a native of the Twin Cities. He did undergraduate work at Stanford University and then completed an MD and PhD (Immunology) at the Mayo Medical School and Mayo Graduate School in Rochester, MN. He then completed both residency training in Internal Medicine and fellowship training in Hematology at the University of Wisconsin-Madison. Dr. Kaufman joined the faculty at the University of Minnesota in 2002. Dr. Kaufman leads a laboratory in the Stem Cell Institute and Masonic Cancer Center focused on using human stem cells to better understand development of blood cells and related cell types. He is also working to translate new stem cell-based therapies to clinical trials for treatment of cancer, chronic infectious disease, vascular disease, and bone repair.
Honors, Awards, Organizations
Honors and Awards
- Graduation with Departmental Honors, Stanford University Department of Biological Sciences, 1988
- American Society of Hematology (ASH) Scholar Award for Junior Faculty-Basic Research. 2004-2006
- University of Minnesota McKnight Land-Grant Professorship, 2005- 2007 (awarded to most promising junior faculty)
- American Society for Clinical Investigation (ASCI), elected 2009
- Andersen Chair in Stem Cell Biology. 2010- present
- Co-Director, Integrated Center of Cellular Therapy and Regenerative Medicine. International Clinical Research Center, St. Anne’s Hospital. Brno, Czech Republic.
Professional Society Memberships
- American Association for the Advancement of Science, 1999-present
- American Society of Hematology, 2000-present
- American Society for Blood and Marrow Transplantation, 2001-present
- International Society for Experimental Hematology, 2001-present
- International Society for Stem Cell Research, 2003- present
- Minnesota Medical Association, 2005- present
- American Society for Clinical Investigation (ASCI), 2009- present
Areas of Expertise
- Hematopoiesis (Blood cell development)
- Stem Cell biology
- Vascular development
- Immunology and Immunotherapy
- PI on Stem Cell Biology Training Grant
- Blood and Marrow Transplantation
- Hematologic Malignancies
- Dr. Kaufman’s research interests focus on hematopoietic, vascular and osteogenic cell development from human pluripotent stem cells. This research uses both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to define developmental pathways and genetic/cellular mechanisms that mediate production of human blood cells and related cell lineages.
- The Kaufman lab is working to translate these istudies into clinically applicable conditions suitable for clinical trials. Human ESCs and iPSCs cells offer a unique model to investigate basic developmental biology and serve as a therapeutic cell source to replace or repair cells or tissues damaged by disease or other degenerative processes.
For more information visit the KAUFMAN LAB
- Research support from National Institute of Health, International Clinical Research Center (St. Anne’s University Hospital, Brno, Czech Republic), Minnesota Partnership for Biotechnology, Minnesota Ovarian Cancer Alliance, William Lawrence & Blanche Hughes Foundation, Bill and Melinda Gates Foundation.
- Zou L, Kidwai FK, Kopher RA, Moti J, Kellum CA, Westendorf JJ, Kaufman DS. “Use of RUNX2 expression to identify osteogenic progenitor cells derived from human embryonic stem cells.” Stem Cell Reports (in press Jan 2015)
- Ferrell PI, Xi J, Ma C, Adlakha M, Kaufman DS. “The RUNX1 +24 Enhancer and P1 Promoter Identify a Unique Subpopulation of Hematopoietic Progenitor Cells Derived from Human Pluripotent Stem Cells.” Stem Cells (2014 Dec 27) doi: 10.1002/stem.1940. [Epub ahead of print] PMID: 25546363
- Ye L, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, Kaufman DS, Ge Y, Zhang J. “Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells.” Cell Stem Cell (2014 Dec 4) 15(6):750-61.
- Ferrell P, Hexum MK, Kopher RA, Lepley MA, Gussiaas A, and Kaufman DS. “Functional Assessment of Hematopoietic Niche Cells Derived from Human Embryonic Stem Cells.” Stem Cells and Development (2014). 23:1355-63.
- Ni Z, Knorr DA, Bendzick L, Allred J and Kaufman DS. “Suppression of HIV Infection by Nature Killer Cells Derived from Chimeric Receptor CD4ζ Expressing Human Pluripotent Stem Cells.” Stem Cells, (2014). 32:1021-31.
- Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, McCullar V, Miller JS, and Kaufman DS. “Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.” Cytotherapy. (2013). 15, 1297-1306.
- Ran D, Shia W, Lo MC, Fan JB, Knorr DA, Ferrell PI, Ye Z, Yan M, Cheng L, Kaufman DS, and Zhang DE. “RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells.” Blood. (2013). 121(15):2882-90.
- Knorr DA, Ni Z, Hexum MK, Bendzick L, Cooper LJN , Lee DA,, Kaufman DS.. “Clinical Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells For Cancer Therapy.” Stem Cells Translational Medicine. (2013). 2:274-83.
Melissa A. Geller, David A. Knorr, David A. Hermanson, Lee Pribyl, Laura Bendzick, Valarie McCullar, Jeffrey S. Miller, and Dan S. Kaufman. (2013). Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy. 15, 1297-1306.
- Knorr, David A., Zhenya Ni, Melinda K. Hexum, Laura Bendzick, Laurence J. N. Cooper , Dean A. Lee,, and Dan S. Kaufman.. (2013). Clinical Scale Derivation Of Natural Killer Cells From Human Pluripotent Stem Cells For Cancer Therapy. Stem Cells Translational Medicine. 2:274-83.
- Zhenya Ni, David A. Knorr, Christine L. Clouser, Peter Southern, Louis M. Mansky, In-Hyun Park and Dan S. Kaufman. (2011). Anti-HIV Activity of Natural Killer Cells Derived From Human Pluripotent Stem Cells. J. of Virology. 85:43-50.
- Tian, Xinghui, Melinda K. Hexum, Vesselin R. Penchev, Russell J. Taylor, Leonard D. Shultz, and Dan S Kaufman. (2009). Bioluminescent imaging demonstrates transplanted human embryonic stem cell-derived CD34+ cells preferentially develop into endothelial cells. Stem Cells 27:2675-85.
- Kaufman, Dan S. (2009). Toward Clinical Therapies Utilizing Hematopoietic Cells Derived from Human Pluripotent Stem Cells. Blood, 114:3513-3523.
- Woll, Petter S. Bartosz Grzywacz, Xinghui Tian, Rebecca Marcus, Michael R. Verneris and Dan S. Kaufman. (2009). Human embryonic stem cells differentiate into a unique population of natural killer cells with highly potent in vivo anti-tumor activity. Blood,113: 6094-6101.
- Martin, Colin H., P. S. Woll, J.-C. Zuniga-Pflucker and Dan S. Kaufman. (2008). Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells. Blood. 112: 2730-2737.
- Woll, Petter S. J.K. Morris, M.S. Painschab, R.K. Marcus, A.D. Kohn, T.L. Biechele, R.T. Moon, and D.S. Kaufman. (2008). Wnt signaling promotes hemato-endothelial cell development from human embryonic stem cells. Blood, 111: 122-131.
- Wilber, Andrew, Jonathan L. Linehan, Xinghui Tian, Petter S. Woll, Julie K. Morris, Lalitha R. Belur, R. Scott McIvor, and Dan S. Kaufman. (2007). Use of the Sleeping Beauty Transposon System for Genetic Engineering of Human Embryonic Stem Cell-derived Hematopoietic Cells. Stem Cells, 25; 2919-2927.
- Kaufman, Dan S., Eric T. Hanson, Rachel L. Lewis, Robert Auerbach, and James A. Thomson. (2001). Hematopoietic colony forming cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA. 98:10716-10721